Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1991 1
1992 3
1993 2
1994 4
1995 3
1996 2
1997 2
1998 6
1999 4
2000 3
2001 2
2002 3
2003 6
2004 7
2005 8
2006 5
2007 21
2008 20
2009 20
2010 18
2011 19
2012 17
2013 16
2014 18
2015 8
2016 15
2017 20
2018 14
2019 25
2020 21
2021 21
2022 30
2023 17

Text availability

Article attribute

Article type

Publication date

Search Results

339 results

Results by year

Filters applied: . Clear all
Page 1
EULAR definition of difficult-to-treat rheumatoid arthritis.
Nagy G, Roodenrijs NMT, Welsing PM, Kedves M, Hamar A, van der Goes MC, Kent A, Bakkers M, Blaas E, Senolt L, Szekanecz Z, Choy E, Dougados M, Jacobs JW, Geenen R, Bijlsma HW, Zink A, Aletaha D, Schoneveld L, van Riel P, Gutermann L, Prior Y, Nikiphorou E, Ferraccioli G, Schett G, Hyrich KL, Mueller-Ladner U, Buch MH, McInnes IB, van der Heijde D, van Laar JM. Nagy G, et al. Among authors: szekanecz z. Ann Rheum Dis. 2021 Jan;80(1):31-35. doi: 10.1136/annrheumdis-2020-217344. Epub 2020 Oct 1. Ann Rheum Dis. 2021. PMID: 33004335 Free PMC article.
[Post-acute COVID-19 syndrome].
Szekanecz Z, Vályi-Nagy I. Szekanecz Z, et al. Orv Hetil. 2021 Jul 4;162(27):1067-1078. doi: 10.1556/650.2021.32282. Orv Hetil. 2021. PMID: 34224394 Review. Hungarian.
Low dose, add-on prednisolone in patients with rheumatoid arthritis aged 65+: the pragmatic randomised, double-blind placebo-controlled GLORIA trial.
Boers M, Hartman L, Opris-Belinski D, Bos R, Kok MR, Da Silva JA, Griep EN, Klaasen R, Allaart CF, Baudoin P, Raterman HG, Szekanecz Z, Buttgereit F, Masaryk P, Klausch LT, Paolino S, Schilder AM, Lems WF, Cutolo M; GLORIA Trial consortium. Boers M, et al. Among authors: szekanecz z. Ann Rheum Dis. 2022 Jul;81(7):925-936. doi: 10.1136/annrheumdis-2021-221957. Epub 2022 May 31. Ann Rheum Dis. 2022. PMID: 35641125 Free PMC article. Clinical Trial.
EULAR points to consider for the management of difficult-to-treat rheumatoid arthritis.
Nagy G, Roodenrijs NMT, Welsing PMJ, Kedves M, Hamar A, van der Goes MC, Kent A, Bakkers M, Pchelnikova P, Blaas E, Senolt L, Szekanecz Z, Choy EH, Dougados M, Jacobs JW, Geenen R, Bijlsma JW, Zink A, Aletaha D, Schoneveld L, van Riel P, Dumas S, Prior Y, Nikiphorou E, Ferraccioli G, Schett G, Hyrich KL, Mueller-Ladner U, Buch MH, McInnes IB, van der Heijde D, van Laar JM. Nagy G, et al. Among authors: szekanecz z. Ann Rheum Dis. 2022 Jan;81(1):20-33. doi: 10.1136/annrheumdis-2021-220973. Epub 2021 Aug 18. Ann Rheum Dis. 2022. PMID: 34407926 Free PMC article.
[Physiotherapy of cancer patients].
Gomez I, Szekanecz É, Szekanecz Z, Bender T. Gomez I, et al. Among authors: szekanecz z. Orv Hetil. 2016 Jul;157(31):1224-31. doi: 10.1556/650.2016.30502. Orv Hetil. 2016. PMID: 27476518 Review. Hungarian.
Risk of major adverse cardiovascular events with tofacitinib versus tumour necrosis factor inhibitors in patients with rheumatoid arthritis with or without a history of atherosclerotic cardiovascular disease: a post hoc analysis from ORAL Surveillance.
Charles-Schoeman C, Buch MH, Dougados M, Bhatt DL, Giles JT, Ytterberg SR, Koch GG, Vranic I, Wu J, Wang C, Kwok K, Menon S, Rivas JL, Yndestad A, Connell CA, Szekanecz Z. Charles-Schoeman C, et al. Among authors: szekanecz z. Ann Rheum Dis. 2023 Jan;82(1):119-129. doi: 10.1136/ard-2022-222259. Epub 2022 Sep 22. Ann Rheum Dis. 2023. PMID: 36137735 Free PMC article.
EULAR recommendations for cardiovascular risk management in rheumatic and musculoskeletal diseases, including systemic lupus erythematosus and antiphospholipid syndrome.
Drosos GC, Vedder D, Houben E, Boekel L, Atzeni F, Badreh S, Boumpas DT, Brodin N, Bruce IN, González-Gay MÁ, Jacobsen S, Kerekes G, Marchiori F, Mukhtyar C, Ramos-Casals M, Sattar N, Schreiber K, Sciascia S, Svenungsson E, Szekanecz Z, Tausche AK, Tyndall A, van Halm V, Voskuyl A, Macfarlane GJ, Ward MM, Nurmohamed MT, Tektonidou MG. Drosos GC, et al. Among authors: szekanecz z. Ann Rheum Dis. 2022 Jun;81(6):768-779. doi: 10.1136/annrheumdis-2021-221733. Epub 2022 Feb 2. Ann Rheum Dis. 2022. PMID: 35110331
EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015/2016 update.
Agca R, Heslinga SC, Rollefstad S, Heslinga M, McInnes IB, Peters MJ, Kvien TK, Dougados M, Radner H, Atzeni F, Primdahl J, Södergren A, Wallberg Jonsson S, van Rompay J, Zabalan C, Pedersen TR, Jacobsson L, de Vlam K, Gonzalez-Gay MA, Semb AG, Kitas GD, Smulders YM, Szekanecz Z, Sattar N, Symmons DP, Nurmohamed MT. Agca R, et al. Among authors: szekanecz z. Ann Rheum Dis. 2017 Jan;76(1):17-28. doi: 10.1136/annrheumdis-2016-209775. Epub 2016 Oct 3. Ann Rheum Dis. 2017. PMID: 27697765 Review.
339 results